| Drug General Information |
| Drug ID |
D09RON
|
| Former ID |
DIB001285
|
| Drug Name |
LY-2300559
|
| Synonyms |
MGlu2 Pot/Cys (migraine prevention), Eli Lilly; Metabotropic glutamate 2 receptor potentiator/cysteinyl leukotriene receptor 1 antagonist (migraine), Eli Lilly; Mglu2 potentiator/CysLT1 antagonist (migraine prevention), Eli Lilly
|
| Indication |
Migraine [ICD9: 346; ICD10:G43]
|
Discontinued in Phase 2 |
[1]
|
|---|
| Company |
Eli Lilly & Co
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Metabotropic glutamate receptor 2 |
Target Info |
Modulator |
|
|---|
| Cysteinyl leukotriene receptor 1 |
Target Info |
Modulator |
|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Glutamatergic synapse
|
|
Cocaine addictionhsa04020:Calcium signaling pathway
|
|
NetPath Pathway
|
TGF_beta_Receptor Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
IL3 Signaling Pathway
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Ionotropic glutamate receptor pathway
|
|
Metabotropic glutamate receptor group II pathway
|
|
Pathway Interaction Database
|
Endothelins
|
|
Reactome
|
G alpha (i) signalling events
|
|
Class C/3 (Metabotropic glutamate/pheromone receptors)R-HSA-391906:Leukotriene receptors
|
|
G alpha (q) signalling events
|
|
WikiPathways
|
GPCRs, Class C Metabotropic glutamate, pheromone
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR downstream signaling
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01184508) A Study in Migraine Prevention. U.S. National Institutes of Health. |
|---|
